Treatment of patients with evidence of mast cell-mediated itch in the absence of hives with omalizumab

Figures & data

Table 1. Patient demographics, PP-NRS scores, and follow-up time of improvement of patients.

Characteristics	Number (n = 6)
Sex, No. (%)	M : F = 2 (33) : 4(67)
Age at diagnosis (years), mean ± S.D.	47.67 ± 13.52
Duration of itch (years), mean ± S.D.	20.17 ± 21.78
Initial PP-NRS, median [IQR]	9 [6 – 10]
Final PP-NRS, median [IQR]	2.5 [0 – 5]
PP-NRS reduction, mean ± S.D.	6 ± 3.16
Follow-up period of treatment of patients (months), median [IQR]	8.52 [2.30 − 13.35]

Figure 1. Peak pruritus-numerical rating scale (PP-NRS) itch score of patients over time. Improvement of PP-NRS itch score with omalizumab treatment in 6 patients over time (p = 0.03, Wilcoxon signed-rank nonparametric test).